Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegaly

Clinical Endocrinology

Volumn 64, Issue 2, 2006, Pages 209-214

  Caron, Philippe ^a,e   Cogne, Muriel ^a   Raingeard, Isabelle ^b   Bex Bachellerie, Véronique ^c   Kuhn, Jean Marc ^d  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LANREOTIDE AUTOGEL; SOMATOMEDIN; SOMATOMEDIN I; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGE DISTRIBUTION; ARTICLE; CAUSE OF DEATH; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; GALLSTONE FORMATION; GASTROINTESTINAL DISEASE; GRANULOMA; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; LUNG EMBOLISM; MALE; PARTICLE SIZE; PRIORITY JOURNAL; SEX DIFFERENCE; TITRIMETRY;

ACROMEGALY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HORMONES; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; LONG-TERM CARE; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 33645025605     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02450.x     Document Type: Article

References (26)

1. Freda P.U. 2002 Somatostatin analogs in acromegaly Journal of Clinical Endocrinology and Metabolism 87 3013 3018
2. Melmed S. Casanueva F.F. Cavagnini F. Chanson P. Frohman L. Grossman A. Ho K. Kleinberg D. Lamberts S. Laws E. Lombardi G. Vance M.L. von Werder K. Wass J. Guistina A. 2002 Guidelines for acromegaly management Journal of Clinical Endocrinology and Metabolism 87 4054 4058
3. Caron Ph. Beckers A. Cullen D.R. Goth M.I. Gutt B. Lauberg P. Pico A.H. Valimaki M. Zgliczynsk W. 2002 Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly Journal of Clinical Endocrinology and Metabolism 87 99 104
4. Ashwell S.G. Bevan J.S. Edwards O.M. Harris M.M. Holmes C. Middleton M.A. James R.A. 2004 The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR European Journal of Endocrinology 150 473 480
5. Van Thiel S.W. Romijn J.A. Biermasz N.R. Ballieux B.E.P.M. Frölich M. Smit J.W.A. Corssmit E.P.M. Roelfsema F. Pereira A.M. 2004 Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients European Journal of Endocrinology 150 489 495
6. Alexopoulou O. Abrams P. Verhelst J. Poppe K. Velkeniers B. Abstract R. Maiter D. 2004 Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR European Journal of Endocrinology 151 317 324
7. Caron Ph Bex M. Cullen D.R. Feldt-Rasmussen U.F. Pico Alfonso A.M. Pynka S. Racz K. Schopohl J.S. Tabarin A. Valimaki M.M.J. The Group for Lanreotide Autogel® Long-Term Study on Acromegaly 2004 One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel Clinical Endocrinology 60 734 740
8. Ikuyama S. Nawata H. Kato K. Ibayashi H. Nakagaki H. 1986 Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients Journal of Clinical Endocrinology and Metabolism 62 729 733
9. Reubi J.C. Landolt A.M. 1989 The growth hormone responses to octreotide in acromegaly correlate with adenoma sandostatin receptor status Journal of Clinical Endocrinology and Metabolism 68 844 850
10. Lamberts S.W. van der Lely A.J. de Herder W.W. Hofland L.J. 1996 Octreotide New England Journal of Medicine 334 246 254
11. Sassolas G. Harris A.G. James-Deidier, French SMS 201- Acromegaly Study Group. 1990 Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients Journal of Clinical Endocrinology and Metabolism 71 391 397
12. Saveanu A. Gunz G. Dufour H. Caron P. Fina F. Ouafik L. Culler M.D. Moreau J.P. Enjalbert A. Jaquet P. 2001 BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas Journal of Clinical Endocrinology and Metabolism 86 140 145
13. Barnard L.B. Grantham W.G. Lamberton P. O'Dorisio T.M. Jackson I.M. 1986 Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995) Annals of Internal Medicine 105 856 861
14. Heron I. Thomas F. Dero M. Gancel A. Ruiz J.M. Schatz B. Kuhn J.M. 1993 Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly Journal of Clinical Endocrinology and Metabolism 76 721 727
15. Morange I. De Boisvilliers F. Chanson P. Lucas B. Dewailly D. Catus F. Thomas F. Jaquet P. 1994 Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide Journal of Clinical Endocrinology and Metabolism 79 145 151
16. Caron P. Cogne M. Gusthiot-Joudet B. Wakim S. Catus F. Bayard F. 1995 Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995) European Journal of Endocrinology 132 320 325
17. Giusti M. Gussoni G. Cuttica C.M. Giordano G. 1996 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group Journal of Clinical Endocrinology and Metabolism 81 2089 2097
18. Newman C.B. Melmed S. George A. Torigian D. Duhaney M. Snyder P. Young W. Klibanski A. Molitch M.E. Gagel R. Sheeler L. Cook D. Malarkey W. Jackson I. Lee Vance M. Barkan A. Frohman I. Kleinberg D.L. 1998 Octreotide as primary therapy for acromegaly Journal of Clinical Endocrinology and Metabolism 83 3034 3040
19. Baldelli R. Colao A. Razzore P. Jaffrain-Rea M.-L. Marzullo P. Ciccarelli E. Ferretti E. Ferone D. Gaia D. Camanni F. Lombardi G. Tamburrano G. 2000 Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) Journal of Clinical Endocrinology and Metabolism 85 4099 4103
20. Colao A. Ferone D. Marzullo P. Cappabianca P. Cirillo S. Boerlin V. Lancranjan I. Lombardi G. 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly Journal of Clinical Endocrinology and Metabolism 86 2779 2786
21. Bevan J.S. Atkin S.L. Atkinson A.B. Bouloux P.-M. Hanna F. Harris P.E. James R.A. McConnell M. Roberts G.A. Scanlon M.F. Stewart P.M. Teasdale E. Turner H.E. Wass J.A.H. Wardlaw J.M. 2002 Primary medical treatment for acromegaly: an open prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-1, and tumor size Journal of Clinical Endocrinology and Metabolism 87 4554 4563
22. Amato G. Mazziotti G. Rotondi M. Iorio S. Doga M. Sorvillo F. Manganella G. Di Salle F. Guistina A. Carella C. 2002 Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly Clinical Endocrinology 56 65 71
23. Ayuk J. Stewart S.E. Stewart P.M. Sheppard M.C. 2002 Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly Journal of Clinical Endocrinology and Metabolism 87 4142 4146
24. Fawcett H.A. Smith N.P. 1984 Injection-site granuloma due to aluminum Archives of Dermatology 120 1318 1322
25. Whitaker I.S. Fazel M.Z. Joshi H.B. Moseley R.P. Turner W.H. 2002 Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injection sites BJU International 90 350
26. Rideout D.J. Graham M.M. 2001 Buttock granulomas: a consequence of intramuscular injection of Sandostatin detected by In-111 Octreoscan Clinical Nuclear Medicine 26 650